| Trade Date | Insider | Title | Buy or Sell | Quantity | Security Type | Price | Proceeds | Transaction Conviction | Position Quantity | Position Value | Positon Conviction | SEC Link | Nature of Ownership | 2020-06-16 | James E Flynn | - | Buy | 225,000 | Common Stock | $19.00 | -$4,275,000.00 | 48.69 [ Very High ] | 1,186,215 | $22,538,085.00 | 256.68 [Very High] | Form 4 | Through Deerfield Partners, L.P. | 2020-06-16 | James E Flynn | - | Buy | 257,883 | Common Stock | $0.00 | $0.00 | - | 961,215 | $0.00 | 208.00 [Very High] | Form 4 | Through Deerfield Partners, L.P. | 2020-06-16 | James E Flynn | - | Buy | 703,332 | Common Stock | $0.00 | $0.00 | - | 703,332 | $0.00 | 152.19 [Very High] | Form 4 | Through Deerfield Partners, L.P. | 2020-06-16 | Zone Healthcare Holdings, Llc | - | Buy | 1,518,819 | Common Stock | $0.00 | $0.00 | - | 1,518,819 | $0.00 | - | Form 4 | - | 2020-06-16 | Zone Healthcare Holdings, Llc | - | Buy | 400,000 | Common Stock | $19.00 | -$7,600,000.00 | - | 1,918,819 | $36,457,561.00 | - | Form 4 | - | 2020-06-16 | William Seybold | - | Buy | 1,518,819 | Common Stock | $0.00 | $0.00 | - | 1,518,819 | $0.00 | - | Form 4 | - | 2020-06-16 | William Seybold | - | Buy | 400,000 | Common Stock | $19.00 | -$7,600,000.00 | - | 1,918,819 | $36,457,561.00 | - | Form 4 | - | 2020-06-16 | Invus Public Equities, L.p. | - | Buy | 2,014,191 | Common Stock | $0.00 | $0.00 | - | 2,014,191 | $0.00 | - | Form 4 | - | 2020-06-16 | Invus Public Equities, L.p. | - | Buy | 800,000 | Common Stock | $19.00 | -$15,200,000.00 | - | 2,814,191 | $53,469,629.00 | - | Form 4 | - | 2020-06-16 | Rowland Charles A Jr | - | Buy | 50,627 | Common Stock | $0.00 | $0.00 | - | 50,627 | $0.00 | - | Form 4 | - | 2020-06-16 | Rowland Charles A Jr | - | Buy | 30,000 | Common Stock | $19.00 | -$570,000.00 | - | 80,627 | $1,531,913.00 | - | Form 4 | - | 2020-06-16 | Gustav Christensen | - | Buy | 88,961 | Common Stock | $0.00 | $0.00 | - | 131,422 | $0.00 | - | Form 4 | - | 2020-06-16 | Anthony G. Quinn | - | Buy | 30,376 | Common Stock | $0.00 | $0.00 | - | 72,837 | $0.00 | - | Form 4 | - | 2020-06-16 | Capital, Llc Casdin | - | Buy | 961,215 | Common Stock | $0.00 | $0.00 | - | 961,215 | $0.00 | - | Form 4 | See Footnote | 2020-06-16 | Capital, Llc Casdin | - | Buy | 650,000 | Common Stock | $19.00 | -$12,350,000.00 | - | 1,611,215 | $30,613,085.00 | - | Form 4 | See Footnote | 2020-06-16 | Jason P Rhodes | - | Buy | 10,040,032 | Common Stock | $0.00 | $0.00 | - | 12,630,758 | $0.00 | - | Form 4 | See Footnote | 2020-06-16 | Atlas Venture Fund X, L.p. | - | Buy | 10,040,032 | Common Stock | $0.00 | $0.00 | - | 12,630,758 | $0.00 | - | Form 4 | See Footnote | 2020-06-16 | Catherine Stehman-breen | - | Buy | 5,062 | Common Stock | $0.00 | $0.00 | - | 47,523 | $0.00 | - | Form 4 | - | 2020-06-16 | Geoff Mcdonough | See Remarks | Buy | 113,231 | Common Stock | $0.00 | $0.00 | - | 1,479,080 | $0.00 | - | Form 4 | - | 2020-06-16 | Donald William Nicholson | - | Buy | 56,615 | Common Stock | $0.00 | $0.00 | - | 99,076 | $0.00 | - | Form 4 | - | 2020-06-16 | Wellington Biomedical Innovation Master Investors (cayman) I L.p. | - | Buy | 1,012,546 | Common Stock | $0.00 | $0.00 | - | 1,012,546 | $0.00 | - | Form 4 | - | 2020-06-16 | Wellington Biomedical Innovation Master Investors (cayman) I L.p. | - | Buy | 1,100,000 | Common Stock | $19.00 | -$20,900,000.00 | - | 2,112,546 | $40,138,374.00 | - | Form 4 | - | 2020-08-14 | Mark D. Angelino | Chief Operating Officer | Buy | 62,560 | Common Stock | $0.60 | -$37,536.00 | 13.47 [ Very High ] | 345,637 | $207,382.20 | 74.45 [High] | Form 4 | - | 2020-12-10 | Matthew Stanton | Chief Scientific Officer | Buy | 10,540 | Common Stock | $0.60 | -$6,324.00 | 2.27 [ High ] | 208,694 | $125,216.40 | 44.86 [High] | Form 4 | - | 2020-12-10 | Matthew Stanton | Chief Scientific Officer | Sell | 5,318 | Common Stock | $37.14 | $197,510.52 | 1.14 [ High ] | 203,376 | $7,553,384.64 | 43.72 [High] | Form 4 | - | 2020-12-10 | Matthew Stanton | Chief Scientific Officer | Sell | 4,402 | Common Stock | $38.01 | $167,320.02 | 0.95 [ High ] | 198,974 | $7,563,001.74 | 42.78 [High] | Form 4 | - | 2020-12-10 | Matthew Stanton | Chief Scientific Officer | Sell | 820 | Common Stock | $38.62 | $31,668.40 | 0.18 [ Low ] | 198,154 | $7,652,707.48 | 42.60 [High] | Form 4 | - | 2020-12-15 | Atlas Venture Fund X, L.p. | - | Sell | 1,151,882 | Common Stock | $0.00 | $0.00 | - | 11,478,876 | $0.00 | 2,467.73 [Very High] | Form 4 | See Footnote | 2020-12-15 | Mark D. Angelino | Chief Operating Officer | Buy | 5,301 | Common Stock | $4.59 | -$24,331.59 | 1.14 [ High ] | 350,938 | $1,610,805.42 | 75.44 [High] | Form 4 | - | 2020-12-15 | Mark D. Angelino | Chief Operating Officer | Sell | 4,401 | Common Stock | $34.87 | $153,462.87 | 0.95 [ High ] | 346,537 | $12,083,745.19 | 74.50 [High] | Form 4 | - | 2020-12-15 | Mark D. Angelino | Chief Operating Officer | Sell | 900 | Common Stock | $35.52 | $31,968.00 | 0.19 [ Low ] | 345,637 | $12,277,026.24 | 74.30 [High] | Form 4 | - | 2021-01-11 | Rowland Charles A Jr | - | Buy | 20,408 | Common Stock | $24.50 | -$499,996.00 | 3.74 [ Very High ] | 101,035 | $2,475,357.50 | 18.53 [High] | Form 4 | 2021-01-11 | Donald William Nicholson | - | Buy | 4,081 | Common Stock | $24.50 | -$99,984.50 | 0.75 [ Average ] | 103,157 | $2,527,346.50 | 18.92 [High] | Form 4 | 2021-01-11 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | Buy | 14,820 | Common Stock | $0.60 | -$8,892.00 | 2.72 [ Very High ] | 212,974 | $127,784.40 | 39.07 [High] | Form 4 | 2021-01-11 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | Sell | 6,269 | Common Stock | $27.18 | $170,391.42 | 1.15 [ High ] | 206,705 | $5,618,241.90 | 37.92 [High] | Form 4 | 2021-01-11 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | Sell | 8,042 | Common Stock | $28.02 | $225,336.84 | 1.48 [ High ] | 198,663 | $5,566,537.26 | 36.44 [High] | Form 4 | 2021-01-11 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | Sell | 509 | Common Stock | $28.77 | $14,643.93 | 0.09 [ Very Low ] | 198,154 | $5,700,890.58 | 36.35 [High] | Form 4 | 2021-01-11 | Douglas Kerr | CHIEF MEDICAL OFFICER | Buy | 11,267 | Common Stock | $4.59 | -$51,715.53 | 2.07 [ High ] | 337,825 | $1,550,616.75 | 61.97 [High] | Form 4 | 2021-01-11 | Douglas Kerr | CHIEF MEDICAL OFFICER | Sell | 6,246 | Common Stock | $27.17 | $169,703.82 | 1.15 [ High ] | 331,579 | $9,009,001.43 | 60.82 [High] | Form 4 | 2021-01-11 | Douglas Kerr | CHIEF MEDICAL OFFICER | Sell | 4,721 | Common Stock | $28.05 | $132,424.05 | 0.87 [ High ] | 326,858 | $9,168,366.90 | 59.96 [High] | Form 4 | 2021-01-11 | Douglas Kerr | CHIEF MEDICAL OFFICER | Sell | 300 | Common Stock | $28.80 | $8,640.00 | 0.06 [ Very Low ] | 326,558 | $9,404,870.40 | 59.90 [High] | Form 4 | 2021-01-13 | Geoff Mcdonough | PRESIDENT AND CEO | Sell | 275,000 | Common Stock | $0.00 | $0.00 | - | 1,204,080 | $0.00 | 220.87 [Very High] | Form 4 | 2021-01-13 | Geoff Mcdonough | PRESIDENT AND CEO | Buy | 275,000 | Common Stock | $0.00 | $0.00 | - | 275,000 | $0.00 | 50.44 [High] | Form 4 | By 2020 Trust | 2021-01-14 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | Buy | 5,630 | Common Stock | $0.60 | -$3,378.00 | 1.03 [ High ] | 203,784 | $122,270.40 | 37.38 [High] | Form 4 | 2021-01-14 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | Sell | 2,840 | Common Stock | $31.11 | $88,352.40 | 0.52 [ Average ] | 200,944 | $6,251,367.84 | 36.86 [High] | Form 4 | 2021-01-14 | Matthew Stanton | CHIEF SCIENTIFIC OFFICER | Sell | 2,790 | Common Stock | $34.00 | $94,860.00 | 0.51 [ Average ] | 198,154 | $6,737,236.00 | 36.35 [High] | Form 4 | 2021-01-14 | Tracy Zimmermann | CHIEF DEVELOPMENT OFFICER | Buy | 2,500 | Common Stock | $4.59 | -$11,475.00 | 0.46 [ Average ] | 2,500 | $11,475.00 | 0.46 [Very Low] | Form 4 | 2021-01-14 | Tracy Zimmermann | CHIEF DEVELOPMENT OFFICER | Sell | 2,500 | Common Stock | $33.09 | $82,725.00 | 0.46 [ Average ] | 0 | $0.00 | - | Form 4 | 2021-01-15 | Mark D. Angelino | CHIEF OPERATING OFFICER | Buy | 7,500 | Common Stock | $4.59 | -$34,425.00 | 1.38 [ High ] | 353,137 | $1,620,898.83 | 64.78 [High] | Form 4 | 2021-01-15 | Mark D. Angelino | CHIEF OPERATING OFFICER | Sell | 3,500 | Common Stock | $32.29 | $113,015.00 | 0.64 [ Average ] | 349,637 | $11,289,778.73 | 64.13 [High] | Form 4 | 2021-01-15 | Mark D. Angelino | CHIEF OPERATING OFFICER | Sell | 2,900 | Common Stock | $33.18 | $96,222.00 | 0.53 [ Average ] | 346,737 | $11,504,733.66 | 63.60 [High] | Form 4 | 2021-01-15 | Mark D. Angelino | CHIEF OPERATING OFFICER | Sell | 500 | Common Stock | $34.12 | $17,060.00 | 0.09 [ Very Low ] | 346,237 | $11,813,606.44 | 63.51 [High] | Form 4 | 2021-01-15 | Mark D. Angelino | CHIEF OPERATING OFFICER | Sell | 600 | Common Stock | $34.96 | $20,976.00 | 0.11 [ Low ] | 345,637 | $12,083,469.52 | 63.40 [High] | Form 4 |
|---|
